Professor of Internal Medicine
Department of Internal Medicine I
Bone Marrow Transplantation
Medical University of Vienna
Währinger Gürtel 18-20, 1090 Vienna, Austria
Phone: +43 (0)1 40400 - 44570
FAX: +43 (0)1 40400 - 25110
Predictive and diagnostic biomarkers for graft-versus-host disease; minimal residual disease and donor chimerism; tolerance induction; immune reconstitution after allogeneic hematopoietic stem cell transplantation.
Graft-versus-leukemia effects and tolerance induction in allogeneic hematopoietic stem cell transplantation
Our long-term research interest is to characterize predictive and diagnostic biomarkers for graft-versus-host disease (GvHD) focusing on genomics, proteomics, cellular subsets including effector, memory and regulatory T-cells, B-cells and dendritic cells, cytokines and chemokines in peripheral blood and tissue specimens. We established CD19+CD21low B-cells as diagnostic biomarkers of active chronic GvHD and defined cut-off levels of cellular biomarker for diagnosis of bronchiolitis obliterans in clinically asymptomatic patients after allogeneic hematopoietic stem cell transplantation (HCT).
In addition, we have a long-standing interest in mechanisms leading to tolerance after allogeneic HCT including use of extracorporeal photopheresis and novel immunosuppressive agents.
To assess immune reconstitution after HCT and the impact of chronic GvHD on the immune system, translational research on reconstitution of T-cells, B-cells, NK-cells and dendritic cells after HCT is performed conducting prospective clinical studies.
Furthermore, graft-versus-leukemia effects and clinical strategies for its intensification including posttransplant cellular therapies for eradication of malignant disease are another main interest of our research group.
More information about the various research projects can be found on the homepage of the Department of Internal Medicine I.
Brüggen MC, Klein I, Greinix HT, Bauer W, Kuzmina ZJ, Rabitsch W, Kalhs P, Petzelbauer P, Knobler R, Stingl G, Stary G. Diverse T cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood accepted for publication 12 Nov 2013.
Kuzmina Z, Krenn K, Petkov V, Körmöczi U, Weigl R, Rottal A, Kalhs P, Mitterbauer M, Ponhold L, Dekan G, Greinix HT, Pickl WF. CD19+CD21low B-cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome Blood 121: 1886-1895, 2013
Kuzmina Z, Eder S, Böhm A, Pernicka E, Vormittag L, Kalhs P, Petkov V, Stary G, Nepp J, Knobler R, Just U, Krenn K, Worel N, Greinix HT: Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia 26: 746-756, 2012.
Kuzmina Z, Greinix HT, Weigl R, Körmöczi U, Rottal A, Frantal S, Eder S, Pickl WF: Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease associated dysgammaglobulinemia. Blood 117: 2265 – 2274, 2011